COSA 2013* Clinical Research
Chairs: Alan Coates & Vanessa Blair
OPTiM: a randomised phase 3 trial of talimogene laherparepvec (T-VEC) vs subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of unresected stage IIIB/C and IV melanoma (#48)
4:00 PM
Prognostic Significance, Accuracy and Usefulness of Oncologists Estimates of Survival Time for Patients Starting First Line Chemotherapy for Advanced Non-Small Cell Lung Cancer (ANSCLC) (#49)
4:15 PM
Treatment Outcomes of Rapid Desensitisation Protocols for Chemotherapeutic Agents and Monoclonal Antibodies following Hypersensitivity Reactions. (#50)
4:30 PM
Disease and Patient Characteristics related to Survival in a large population-based cohort of patients with Malignant Pleural Mesothelioma (MPM) (#51)
4:45 PM
Somatic Mutations in Metastatic Melanoma in a large cohort of Australian patients (#52)
5:00 PM
Prognostic Value of Early Objective Tumor Response (EOTR) to First Line Systemic Therapy in Metastatic Colorectal Cancer (Mcrc): Individual Patient Data (IPD) Meta-Analysis of Randomized Trials from the ARCAD Database (#53)
5:15 PM